Neutral endopeptidase-24.11 (neprilysin; NEP/CD10) is a cell surface metallopeptidase expressed by prostatic epithelial cells that degrades various bioactive peptides including endothelin. Endothelin-converting enzyme (ECE), the key enzyme of endothelin biosynthesis, catalyses the final processing step in the pathway. Neuropeptide substrates of NEP, including endothelin, have been implicated in the growth of androgen-independent prostate cancer. We have surveyed the expression of NEP and ECE in a range of prostate cancer cell lines. Western analysis reveals that ECE-1 is expressed abundantly in all the malignant cell lines tested, except for LNCaP. In contrast, LNCaP cells express high levels of NEP, while NEP was not detected in PC-3, DU145 and other metastatic cell lines that were tested. Of the normal immortalized prostate epithelial cell lines, PNT1a shows equivalent amounts of NEP and ECE. PNT2-C2 shows poor NEP expression but an abundance of ECE. P4E6, by comparison, has low levels of both ECE and NEP. These differences in expression may render these cell lines useful in experimental models for future study. Benign prostatic hyperplasia primary epithelial cells express much higher levels of NEP than malignant primary epithelial cells, but neither show ECE expression. On the other hand, surrounding stromal cell populations have detectable ECE levels. An absence of ECE in malignant and benign prostatic hyperplasia cells of primary epithelial origin suggests an important role for stromal interaction and paracrine production of ECE within the host. The upregulation of ECE expression in metastatic cells in culture may be indicative of its role in metastatic progression. A differential profile of ECE and NEP could contribute to an abundance of mitogenic peptides aiding the progression of androgen-independent prostate cancer.
Skip Nav Destination
Article navigation
September 2002
-
Cover Image
Cover Image
Conference Article|
September 01 2002
Differential expression of neutral endopeptidase-24.11 (neprilysin) and endothelin-converting enzyme in human prostate cancer cell lines
Badar A. USMANI;
*School of Biochemistry and Molecular Biology, University of Leeds, Leeds LS2 9JT, U.K.
Dr B.A. Usmani (e-mail [email protected]).
Search for other works by this author on:
Ben HARDEN;
Ben HARDEN
*School of Biochemistry and Molecular Biology, University of Leeds, Leeds LS2 9JT, U.K.
Search for other works by this author on:
Norman J. MAITLAND;
Norman J. MAITLAND
†Yorkshire Cancer Research Unit, Department of Biology, University of York, York YO10 5YW, U.K.
Search for other works by this author on:
Anthony J. TURNER
Anthony J. TURNER
*School of Biochemistry and Molecular Biology, University of Leeds, Leeds LS2 9JT, U.K.
Search for other works by this author on:
Publisher: Portland Press Ltd
Online ISSN: 1470-8736
Print ISSN: 0143-5221
© 2002 The Biochemical Society and the Medical Research Society
2002
Clin Sci (Lond) (2002) 103 (s2002): 314S–317S.
Citation
Badar A. USMANI, Ben HARDEN, Norman J. MAITLAND, Anthony J. TURNER; Differential expression of neutral endopeptidase-24.11 (neprilysin) and endothelin-converting enzyme in human prostate cancer cell lines. Clin Sci (Lond) 1 September 2002; 103 (s2002): 314S–317S. doi: https://doi.org/10.1042/CS103S314S
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Biochemical Society Member Sign in
Sign InSign in via your Institution
Sign in via your InstitutionGet Access To This Article
Open Access for all
We offer compliant routes for all authors from 2025. With library support, there will be no author nor reader charges in 5 journals. Check here |
![]() |